CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr ...
GSK plc (NYSE:GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes ...
Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...
A GSK medicine that was pulled from the market after failing its confirmatory test in multiple myeloma has new data from a Phase 3 study evaluating it as an earlier line of treatment, and the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results